Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.

Antimicrobial agents and chemotherapy - 1 Sept 2013

Sahm D F, Deane J, Pillar C M, Fernandes P

Abstract excerpt

Clinical development of CEM-102 (fusidic acid) has recently begun in the United States for chronic oral treatment of prosthetic joint infections. To support this development, the in vitro activity of fusidic acid against important Staphylococcus aureus clones and resistance phenotypes was determined. Against 51 such isolates, the modal fusidic acid MIC was 0.12 μg/ml (range, 0.06 to 0.25 μg/ml for 49 isolates)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Culture Media

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Microbial Sensitivity Tests

Share to Phenotype

Share to Staphylococcus aureus

Source

Open in PubMed Open full text

Identifiers

PMID: 23774441
DOI: 10.1128/AAC.00206-13
PMCID: PMC3754304

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.PMID 23774441Read ↗

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).Semantic proximity Read ↗

Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.Semantic proximity Read ↗

Fusidic acid resistance in Staphylococcus aureusSemantic proximity Read ↗

Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008.Semantic proximity Read ↗

High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidisSemantic proximity Read ↗

Molecular analysis of fusidic acid resistance in Staphylococcus aureusSemantic proximity Read ↗

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Semantic proximity Read ↗

High Usage of Topical Fusidic Acid and Rapid Clonal Expansion of Fusidic Acid–Resistant Staphylococcus aureus: A Cautionary TaleSemantic proximity Read ↗

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New FluoroquinoloneSemantic proximity Read ↗

Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate.Semantic proximity Read ↗

In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.Semantic proximity Read ↗

Activity of glycylcyclines CL 329998 and CL 331002 against minocycline-resistant and other strains of methicillin-resistant Staphylococcus aureus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.